RNA:NASDAQ, Avidity Biosciences, Inc.

RNA stock overview

Avidity Biosciences, Inc. (RNA:NASDAQ) closed at $8.47 on November 3, 2026, down 0.94% on the day. The stock trades 49.5% below its 52-week high of $16.77 and 13.1% above its 52-week low of $7.49. Avidity Biosciences, Inc. is part of the Health Care sector.

Key figures

Price

$8.47

Day change

-0.94%

Volume

5,812

Average volume

285,051

Market cap

144M+

52-week range

$7.49 – $16.77

50-day average

$9.67

200-day average

$12.06

Price action over the past year

In 252 trading sessions since October 31, 2025, RNA closed higher on 124 days (49%). Its best day was August 19, 2026 (+6.78%) and its worst was February 27, 2026 (-79.74%). The stock moved 10% or more in a single session 3 times.

Recent signals

• Nov 2, 2026: Trading sideways between $7.61 and $8.55 over 30 days (Sideways scanner)
• Nov 2, 2026: Hit a new 1-Month High of $8.55 (New Highs/Lows scanner)
• Nov 2, 2026: News catalyst: Biotech (News Catalysts scanner)
• Sep 8, 2026: Dropped 20.0% in a single session (Dips & Crashes scanner)

RNA news

• Nov 2, 2026: Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026
• Oct 27, 2026: Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
• Oct 27, 2026: Atrium Therapeutics Doses First Patient in Corventis, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
• Oct 20, 2026: Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• Oct 20, 2026: Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing
• Oct 8, 2026: Atrium Therapeutics Announces $50 Million Private Placement
• Sep 6, 2026: Wall Street Money Is Leaving Just As Atrium's (RNA) Pipeline Turns Real
• Sep 2, 2026: Atrium Therapeutics to Participate in Upcoming Investor Conferences

About Avidity Biosciences, Inc.

Avidity Biosciences Inc is a bio-technology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product candidate AOC 1001, is designed to treat a rare monogenic muscle disease.

Similar stocks

• MENS:NASDAQ
• VRXA:NASDAQ
• NGEN:NASDAQ
• CUE:NASDAQ
• TARA:NASDAQ
• IPHA:NASDAQ
• MGNX:NASDAQ
• PDSB:NASDAQ

Find more stocks like RNA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.